LIC PBT up 58.5% on a 2.0% revenue decline, but operating cash fell 22.2%

What changed

Revenue slipped 2.0% to NZD 249.0m from NZD 254.0m, yet profit before tax rose 58.5% to NZD 31.0m and NPAT rose 31.2% to NZD 22.9m. The NPAT gain was held back by a NZD 0.7m after-tax loss from discontinued operations and a higher effective tax rate (23.9% versus 10.6% in FY19), so PBT is the cleaner read on underlying performance. Operating cash flow fell 22.2% to NZD 40.5m, and with capex modestly higher at NZD 7.8m, pre-lease free cash flow dropped to NZD 32.6m from NZD 45.8m. The balance sheet moved the other way: borrowings were cleared (from NZD 1.6m to zero) and cash rose to NZD 18.8m, leaving LIC in a net cash position of NZD 18.8m. Segment mix tilted toward higher-margin lines, with NZ market genetics (39.9% of revenue) and herd testing (14.2%) gaining share while farm automation is no longer separately disclosed.

What matters

• Earnings quality rests on segment mix, not volume. Revenue contracted, but herd testing segment result jumped from NZD 10.8m to NZD 20.1m and farm software result rose from NZD 31.2m to NZD 36.6m. The PBT lift is disproportionately a margin/mix story inside a flat-to-down top line.
• Cash conversion deteriorated sharply. OCF fell NZD 11.6m even as PBT rose NZD 11.4m, and debtor days extended to about 63 from 59. Pre-lease FCF still covers NPAT at 142% and the dividend at 1.8x, but the directional gap between accounting earnings and cash is the most important signal in this release.
• Balance sheet direction is unambiguously positive. Zero gross debt, NZD 18.8m cash, equity of NZD 294.1m, and ROE improving to 7.9% from 6.0% give management capital flexibility that was not as visible a year ago.

Expectations

No stated targets, forward work balance, or quantitative guidance were disclosed, and no interim/anchor shape context was supplied, so seasonality cannot be benchmarked here. Against that blank backdrop, the release supports a read that profitability expanded despite a revenue decline, but it does not support claims about run-rate sustainability, next-period volume recovery, or whether the narrower effective-tax benefit that flattered FY19 will recur. The declared final dividend of 12.51 cents is 1.9% below the prior final of 12.75 cents, which sits at odds with the headline earnings improvement and may itself be a signal about management's own forward view.

Quality of result

Mixed. The durable components are the genuine step-up in herd testing and farm software segment results, the elimination of borrowings, and the improvement in ROE to 7.9%. The timing-assisted components are larger than they first appear: OCF fell NZD 11.6m, debtor days extended by about four days, and the FY19 comparison base was itself depressed by a low effective tax rate, which exaggerates the PBT growth optics somewhat. With payout at 77.6% of NPAT but only 54.6% of pre-lease FCF, the dividend is still covered — but by a thinner margin than the earnings headline implies. An adjusted earnings bridge or non-GAAP KPI reconciliation was not provided, limiting the ability to decompose the margin gain further.

Unresolved

• What specifically drove the NZD 9.3m jump in herd testing segment result on only NZD 3.3m of additional revenue, and is that margin level repeatable?
• Why was farm automation folded out of separate disclosure, and what revenue and result were reclassified into the remaining segments?
• What is behind the NZD 11.6m fall in OCF and the debtor-day extension — customer mix, payment terms, a specific large debtor, or COVID-related timing?
• What is the discontinued operation, and is the NZD 0.7m after-tax loss the final cost or a partial recognition?
• Why was the final dividend cut 1.9% when PBT rose 58.5% and the group moved to net cash?

This briefing cannot assess LIC's competitive position, customer retention, product-level pricing, or the strategic rationale behind the segment restructure, as none of that context was included in the extracted data.

Key metrics

Segment breakdown

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.